Year All20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 09, 2026 Read More BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting May 27, 2026 Read More BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 May 13, 2026 Read More BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update May 06, 2026 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 05, 2026 Read More BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema May 04, 2026 Read More BioCryst to Present at Upcoming Investor Conferences Apr 28, 2026 Read More BioCryst to Report First Quarter 2026 Financial Results on May 6 Apr 15, 2026 Read More BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer Apr 06, 2026 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2026 Read More
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting May 27, 2026 Read More
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 May 13, 2026 Read More
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update May 06, 2026 Read More
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema May 04, 2026 Read More